BIEL: The First Public‑Market Gateway Into AI‑Driven Bioelectric Medicine
This Is a Venture‑Scale Opportunity
Public investors almost never get access to early‑stage AI platform upside.
BIEL + Electrome creates a publicly traded AI‑bioelectric platform at a moment when AI narratives alone have minted billionaires.
FDA deregulation of non‑medical wearable data has recreated the same conditions that allowed early AI giants to explode in value.
The Core Thesis
BIEL has the hardware.
Electrome has the AI.
The new vagus‑nerve patent provides the defensible therapeutic target.
The leadership team provides the execution engine.
Together, they form a platform‑level company, not a device company.
The Patent That Changes the Valuation Ceiling
Utility Patent Application 18/667,971 — Non‑Invasive Vagus Nerve Stimulation (VNS)
Key Value Drivers
Non‑invasive VNS using PEMF — no implants, no surgery.
Targets chronic inflammation, affecting over one‑third of Americans.
Applicable to arthritis, depression, diabetes, cardiovascular issues, autoimmune disorders.
Built on BIEL’s already‑cleared PEMF platform → fastest path to commercialization.
Inventors include Martinez, McLeod, and Staelin — a team with both engineering and commercialization pedigree.
Why This Matters to Investors
VNS is one of the most valuable neuromodulation categories in medicine.
Existing players rely on implants → high cost, high friction, limited scale.
A non‑invasive, wearable VNS device is a category‑defining product with multi‑billion‑dollar potential.
How the Patent Supercharges the AI Narrative
BIEL needed four pieces to become an AI platform:
A brain — Electrome
A story — Ken Mayer
A builder — John Martinez
An operator — Sree Koneru
The vagus‑nerve patent adds the fifth pillar:
A high‑value, defensible therapeutic target that produces rich physiological signals ideal for AI‑driven closed‑loop therapy.
This transforms ActiPatch from a static OTC device into:
A data node
A sensing hub
A closed‑loop AI therapeutic engine
Exactly the architecture behind early AI unicorns.
Why Martinez Is the Technical Billionaire‑Maker
Designed ASICs and firmware for BIEL’s FDA‑cleared devices.
Built advanced sensing and waveform prototypes with Electrome.
Can integrate PEMF + sensing + firmware + BLE + OTA + cloud.
This is the same technical profile behind the engineers who built the platforms that minted AI billionaires.
Why Koneru Is the Strategic Billionaire‑Maker
Aligns incentives, partnerships, regulatory strategy, and business models.
Converts prototypes into revenue and platforms into ecosystems.
Turns technical possibility into commercial inevitability.
This is the operator profile that scaled OpenAI, Anthropic, Inflection, and xAI.
The Overlooked Gold Mine: The Veterinary Market
Veterinary therapeutics is one of the fastest‑growing global health markets.
Chronic inflammation, arthritis, anxiety, and mobility issues are more common in animals than humans.
Animals cannot take many human anti‑inflammatory drugs - drug‑free PEMF and VNS are uniquely valuable.
Regulatory pathways are faster, cheaper, and less restrictive.
Why BIEL Wins
ActiPatch already addresses top veterinary pain points.
Vagus‑nerve stimulation could treat canine arthritis, anxiety, gut inflammation, and post‑operative recovery.
Veterinarians are early adopters and direct resellers.
High‑margin, recurring revenue potential with minimal regulatory cost.
Takeaway
The veterinary vertical alone could become a nine‑figure business, independent of human markets.
The Big Picture: A Multi‑Sector Bioelectric Platform
BIEL is positioned to dominate multiple billion‑dollar verticals:
AI‑driven bioelectric therapeutics
Chronic inflammation management
Non‑invasive vagus nerve stimulation
Wearable health data ecosystems
Human OTC pain
Veterinary therapeutics
Subscription‑based wellness platforms
This is not a penny‑stock device company.
It is a public‑market AI‑bioelectric platform with asymmetric upside.
This Is a Venture‑Scale Opportunity
Public investors almost never get access to early‑stage AI platform upside.
BIEL + Electrome creates a publicly traded AI‑bioelectric platform at a moment when AI narratives alone have minted billionaires.
FDA deregulation of non‑medical wearable data has recreated the same conditions that allowed early AI giants to explode in value.
The Core Thesis
BIEL has the hardware.
Electrome has the AI.
The new vagus‑nerve patent provides the defensible therapeutic target.
The leadership team provides the execution engine.
Together, they form a platform‑level company, not a device company.
The Patent That Changes the Valuation Ceiling
Utility Patent Application 18/667,971 — Non‑Invasive Vagus Nerve Stimulation (VNS)
Key Value Drivers
Non‑invasive VNS using PEMF — no implants, no surgery.
Targets chronic inflammation, affecting over one‑third of Americans.
Applicable to arthritis, depression, diabetes, cardiovascular issues, autoimmune disorders.
Built on BIEL’s already‑cleared PEMF platform → fastest path to commercialization.
Inventors include Martinez, McLeod, and Staelin — a team with both engineering and commercialization pedigree.
Why This Matters to Investors
VNS is one of the most valuable neuromodulation categories in medicine.
Existing players rely on implants → high cost, high friction, limited scale.
A non‑invasive, wearable VNS device is a category‑defining product with multi‑billion‑dollar potential.
How the Patent Supercharges the AI Narrative
BIEL needed four pieces to become an AI platform:
A brain — Electrome
A story — Ken Mayer
A builder — John Martinez
An operator — Sree Koneru
The vagus‑nerve patent adds the fifth pillar:
A high‑value, defensible therapeutic target that produces rich physiological signals ideal for AI‑driven closed‑loop therapy.
This transforms ActiPatch from a static OTC device into:
A data node
A sensing hub
A closed‑loop AI therapeutic engine
Exactly the architecture behind early AI unicorns.
Why Martinez Is the Technical Billionaire‑Maker
Designed ASICs and firmware for BIEL’s FDA‑cleared devices.
Built advanced sensing and waveform prototypes with Electrome.
Can integrate PEMF + sensing + firmware + BLE + OTA + cloud.
This is the same technical profile behind the engineers who built the platforms that minted AI billionaires.
Why Koneru Is the Strategic Billionaire‑Maker
Aligns incentives, partnerships, regulatory strategy, and business models.
Converts prototypes into revenue and platforms into ecosystems.
Turns technical possibility into commercial inevitability.
This is the operator profile that scaled OpenAI, Anthropic, Inflection, and xAI.
The Overlooked Gold Mine: The Veterinary Market
Veterinary therapeutics is one of the fastest‑growing global health markets.
Chronic inflammation, arthritis, anxiety, and mobility issues are more common in animals than humans.
Animals cannot take many human anti‑inflammatory drugs - drug‑free PEMF and VNS are uniquely valuable.
Regulatory pathways are faster, cheaper, and less restrictive.
Why BIEL Wins
ActiPatch already addresses top veterinary pain points.
Vagus‑nerve stimulation could treat canine arthritis, anxiety, gut inflammation, and post‑operative recovery.
Veterinarians are early adopters and direct resellers.
High‑margin, recurring revenue potential with minimal regulatory cost.
Takeaway
The veterinary vertical alone could become a nine‑figure business, independent of human markets.
The Big Picture: A Multi‑Sector Bioelectric Platform
BIEL is positioned to dominate multiple billion‑dollar verticals:
AI‑driven bioelectric therapeutics
Chronic inflammation management
Non‑invasive vagus nerve stimulation
Wearable health data ecosystems
Human OTC pain
Veterinary therapeutics
Subscription‑based wellness platforms
This is not a penny‑stock device company.
It is a public‑market AI‑bioelectric platform with asymmetric upside.
1
